Physician

Edmund Gerard Lacour, M.D.

According to 2025 Medicare claims, Edmund Lacour, M.D. (NPI: 1285689463) practices rheumatology in the Dothan, AL market, with the plurality of this provider's patient population coming from Houston, AL. This provider's primary affiliated billing organization is DOTHAN MEDICAL ASSOCIATES, P.C. (NPI: 1972693778; TIN: 630991466) and primary practice location at 36301-3001. Lacour is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Lacour's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,453 traditional Medicare patients, billed 352,281 HCPCS/CPT codes, and received $4,619,150 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 6,914 prescription claims across 1,185 beneficiaries totaling $12,224,501 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2016 DME data shows 11 claims. Open Payments data shows 94 records totaling $23,491. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,624,481 to $12,224,501. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $4,701 to $2,797.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,877	289,846	$3,889,304
2016	1,850	334,852	$4,258,705
2017	1,643	316,647	$4,851,134
2018	1,648	269,741	$5,416,553
2019	1,483	248,178	$4,905,333
2020	1,428	252,521	$4,722,490
2021	1,447	288,108	$4,393,296
2022	1,485	313,361	$4,369,382
2023	1,567	353,611	$4,458,370
2024	1,453	352,281	$4,619,150

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	916	11,935	$3,624,481
2016	947	12,221	$4,166,047
2017	959	12,127	$4,153,322
2018	1,106	12,341	$6,004,520
2019	1,137	12,109	$7,351,300
2020	1,163	11,637	$8,303,599
2021	1,250	12,131	$10,117,678
2022	1,379	13,223	$12,185,387
2023	1,415	10,650	$10,782,032
2024	1,185	6,914	$12,224,501

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	11	$1,833
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	727	1,421	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	617	871	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	615	916	$12
96372	Injection of drug or substance under skin or into muscle	536	1,486	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	557	1,464	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	225	6,694	$2,070,157
Enbrel Sureclick	Etanercept	201	6,020	$1,562,056
Rinvoq	Upadacitinib	222	6,900	$1,470,273
Stelara	Ustekinumab	54	4,088	$1,050,948
Skyrizi Pen	Risankizumab-Rzaa	27	2,100	$553,123

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	64	$1,669	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	30	$21,821	SUN PHARMACEUTICAL INDUSTRIES INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Edmund Gerard Lacour, M.D.?

Tedicare shows public-source Medicare data for Edmund Gerard Lacour, M.D. (NPI 1285689463), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Edmund Gerard Lacour, M.D. have ACO affiliation data?

Edmund Gerard Lacour, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Edmund Gerard Lacour, M.D.?

Edmund Gerard Lacour, M.D. is linked to DOTHAN MEDICAL ASSOCIATES, P.C. (billing NPI 1972693778) in the available physician profile data.

Does Edmund Gerard Lacour, M.D. have Open Payments data?

Edmund Gerard Lacour, M.D. has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.